logo
  

Omnicare Q2 Profit Down - Update

Pharmaceutical services provider Omnicare Inc. (OCR), Wednesday said its profit for the second quarter dropped from a year ago, hurt by loss from discontinued operations that offset a 7 percent growth in revenues. Moving ahead, the company maintained its financial outlook for the year.

Cincinnati, Ohio-based Omnicare's second-quarter profit dropped to $21.97 million or $0.21 per share from $52.22 million or $0.48 per share a year ago.

Income from continuing operations rose to $61.25 million or $0.58 per share from $47.30 million or $0.43 per share last year. Adjusted cash earnings for the quarter rose to $0.91 per share from $0.85 per share a year ago.

On average, nine analysts polled by Thomson Reuters expected earnings of $0.90 per share for the quarter. Analysts' estimates typically exclude special items.

Omnicare said its sales for the second quarter grew 7.1 percent to $1.61 billion from $1.50 billion last year. Sales at its core Long-Term Care business rose 2.7 percent to $1.19 billion, while Specialty Care group jumped 22 percent to $420 million.

Wall Street analysts had a consensus revenue estimate of $1.59 billion for the quarter.

Moving ahead, the company continues to expect adjusted cash earnings of $3.64 to $3.72 per share and revenues of $6.3 billion to $6.4 billion for full year 2014.

Analysts currently expect full-year earnings of $3.69 per share on revenues of $6.37 billion.

Meanwhile, the company lifted its guidance for cash flows from operations to a range of $500 million to $550 million, from its prior outlook of $475 million to $550 million.

OCR is currently trading at $63.01, down $2.02 or 3.11%, on the NYSE.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lincoln Park, New Jersey -based ConSup North America Inc. is recalling around 85,984 pounds of ready-to-eat or RTE sliced prosciutto ham product produced in Germany without the benefit of equivalent inspection, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and...

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT